CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease. - Wikidata - wikimedia - TriplyDB

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

http://www.wikidata.org/entity/Q45179286

about

Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study.Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population.Tumour necrosis factor-alpha polymorphism increases risk of nonvariceal upper gastrointestinal bleeding among patients taking proton pump inhibitors.The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.

P2860

Q34706677-261C2CB9-DA00-4383-A7C6-614210ECA6A8 Q35137054-A58BE0B0-3B6A-4E64-AD9E-1E251F50BFC8 Q35809238-ABC620FB-BB3C-4E66-9036-EB9D353CC65F Q36440202-0E227D5C-EBBA-4C64-AC53-BE9DBEAE94A7 Q36469405-5CE1E9B3-4C4E-4601-833D-D76172E08B82 Q40471212-DE2B345B-9DE7-40DA-8104-CA42358DFDA4 Q41432957-744B364A-1F40-405E-B38A-A1D5B59B8F44 Q42315488-9784D64F-71C0-4876-B897-C4E80C0FABFD Q42955912-8F3E48F5-0186-4E26-8C9A-77AB06345A38 Q52685824-2072EABF-D09A-4CB5-B610-11378633278B

P2860

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

http://www.wikidata.org/entity/Q45179286

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

@en

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

@nl

type

label

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

@en

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

@nl

prefLabel

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

@en

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.

@nl

P1433

Q45179286-22D8363A-E384-49C1-9B62-0510A96E5516

P1476

Q45179286-3A82B53E-532D-4D60-8143-74D436E6095E

P2093

Q45179286-005B590D-836F-4A83-91DD-7C6F4844056C

Q45179286-4E132994-C9D6-4EDB-BDF9-EC9FCF6E69D6

Q45179286-6B90BB37-5CF2-4866-B110-A1903C38A055

Q45179286-774D8B78-2557-4902-90E2-688ED4A68BF5

Q45179286-B484FDD9-9726-4C97-8686-87DE5299A24E

P2860

Q45179286-028F3423-E7EC-40EC-ACDD-77956E25453B

Q45179286-0FD1EBA2-C7B3-4D3D-87E1-00F57FF467CB

Q45179286-10965453-912A-4595-A525-872D3AD9F7E2

Q45179286-1555626C-B837-4FC8-A699-076AC759D47F

Q45179286-1E67CDA7-5B97-4E71-B7A0-B596744CF29C

Q45179286-20D30F32-AD99-45C3-A20A-E1866AF9F5DC

Q45179286-29332F52-4FAF-4FAD-AB0C-C809631AC351

Q45179286-2EBFA10E-F508-47FD-AD3F-3CF3299CB428

Q45179286-330CC817-CA57-40FC-980C-A6749250A0DC

Q45179286-3937AE78-5D78-4680-88A2-CDD974E23027

P304

Q45179286-D0E5FA25-8DF6-44B5-BEB2-90596B22FE06

P31

Q45179286-799270D0-7BAF-44B2-972D-14ECC6EB491F

P356

Q45179286-56DC02D4-89E7-4017-8C17-8C9F082F42CF

P407

Q45179286-C19E65AA-E82F-4C85-B561-386E99D0CC1A

P433

Q45179286-8A10C93F-0960-4432-8D45-68E31CEC08FD

P478

Q45179286-678492AD-9E5A-4AFF-AA98-0AA8E192FE59

P50

Q45179286-3935787C-F35C-4F1F-AAD9-132F89D3B4D1

Q45179286-A08444A1-3CDE-4A1C-9406-4237B826EAA6

Q45179286-FD8F3564-7278-49C6-AC8E-177A43B6082B

Q45179286-FF053F99-44BF-49E5-ACB6-14372E943DD3

P577

Q45179286-013E600A-4EDC-4476-B39B-4C641CB5F00A

P5875

Q45179286-1343CD12-3A94-4E87-A58F-137B79AB251E

P698

Q45179286-075862F7-F9C5-4103-AB83-C5A67F077FD5

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease

@en

P2093

A Jorgensen

http://www.w3.org/2001/XMLSchema#string

C O Musumba

http://www.w3.org/2001/XMLSchema#string

D Van Eker

http://www.w3.org/2001/XMLSchema#string

E Zhang

http://www.w3.org/2001/XMLSchema#string

N O'Hara

http://www.w3.org/2001/XMLSchema#string

P2860

Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function

The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population

P-450 metabolites of arachidonic acid in the control of cardiovascular function

CYP2C19*17 is associated with decreased breast cancer risk.

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.

Endoscopy in gastrointestinal bleeding.

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

P304

195-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2012.215

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Munir Pirmohamed

David Mark Pritchard

P577

2012-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233989327

http://www.w3.org/2001/XMLSchema#string

P698

23267857

http://www.w3.org/2001/XMLSchema#string